{"text": "Administration of rhNGF was safe, with few adverse events attributed to treatment apart from injection site pain/hyperalgesia and other pain syndromes.", "user_data": {"pmid": "11056593"}}
{"text": "However, neither the primary end point (P =.25) nor most of the secondary end points demonstrated a significant benefit of rhNGF.", "user_data": {"pmid": "11056593"}}
{"text": "Exceptions were the global symptom assessment (P =.03) and 2 of 32 comparisons within the PBQ, which showed a modest but significant benefit of rhNGF (P =.05 for severity of pain in the legs and P =.003 for 6-month symptoms in the feet and legs).", "user_data": {"pmid": "11056593"}}
{"text": "The patients were assigned to two groups.", "user_data": {"pmid": "11196396"}}
{"text": "Twenty-six patients, aged 21 to 36 years (mean age 27), received only fluoxetine 20 mg/day (1 capsule) for a week which was later increased to 40 mg/day (2 capsules).", "user_data": {"pmid": "11196396"}}
{"text": "Seventeen patients, aged 19 to 48 years (mean age 31), were given fluoxetine 20 mg/day plus local application of lidocaine ointment.", "user_data": {"pmid": "11196396"}}
{"text": "The patients and partners were re-evaluated 8 weeks after the treatment.", "user_data": {"pmid": "11196396"}}
{"text": "The results were classified as unsuccessful, improvement and cure.", "user_data": {"pmid": "11196396"}}
{"text": "The chi-square test was used for statistical analysis.", "user_data": {"pmid": "11196396"}}
{"text": "In the fluoxetine group, 8 (30.8%) patients cured, 11 (42.2%) showed improvement and there were 7 failures (26.9%).", "user_data": {"pmid": "11196396"}}
{"text": "In the combination treatment group, 9 (52.9%) patients cured, improvement was observed in 5 (29.4%) and failure in 3 (17.6%).", "user_data": {"pmid": "11196396"}}
{"text": "There were no statistical differences between the two groups according to the side effects (p > 0.01).", "user_data": {"pmid": "11196396"}}
{"text": "No patients were excluded from the study due to side effects.", "user_data": {"pmid": "11196396"}}
{"text": "The mean daily insulin dose after 24 weeks of treatment was 16.4 +/- 10.1 IU in the acarbose group and 22.4 +/- 12.2 IU in the placebo group (mean +/- s.d.; p < 0.07).", "user_data": {"pmid": "11228756"}}
{"text": "Postprandial increases in blood glucose, insulin and C-peptide were consistently lower in the acarbose-treated group than in the placebo group.", "user_data": {"pmid": "11228756"}}
{"text": "For example, the mean increase in 2-h postprandial serum insulin remained almost unchanged in the acarbose group at the end of 24 weeks of treatment compared to an increase to 43 +/- 29 microU/ml (mean +/- s.d.) at the end of the study period for the placebo group.", "user_data": {"pmid": "11228756"}}
{"text": "The infusions produced similar nicotine levels in both groups.", "user_data": {"pmid": "11422660"}}
{"text": "Only minor differences were seen in FFA levels, pulse rates and blood pressure.", "user_data": {"pmid": "11422660"}}
{"text": "A total of nine patients died.", "user_data": {"pmid": "11579299"}}
{"text": "Mean blood pressure fell to 146/79 mm Hg (17/11) in losartan patients and 148/79 mm Hg (19/11) in atenolol patients.", "user_data": {"pmid": "11937179"}}
{"text": "The primary endpoint occurred in 103 patients assigned losartan (n=586) and 139 assigned atenolol (n=609); relative risk 0.76 (95% CI 0.58-.98), p=0.031.", "user_data": {"pmid": "11937179"}}
{"text": "38 and 61 patients in the losartan and atenolol groups, respectively, died from cardiovascular disease; 0.63 (0.42-0.95), p=0.028.", "user_data": {"pmid": "11937179"}}
{"text": "Mortality from all causes was 63 and 104 in losartan and atenolol groups, respectively; 0.61 (0.45-0.84), p=0.002.", "user_data": {"pmid": "11937179"}}
{"text": "As the drop-out rate after crossover was high (17 of 79 patients [22%]), we analyzed the trial as a parallel clinical trial, using data of the first half of the crossover phase only.", "user_data": {"pmid": "12401759"}}
{"text": "At 16 weeks, mean HbA(1c) was 0.84% (95% CI -1.31 to -0.36) lower in the continuous subcutaneous insulin infusion group compared with the insulin injection group (P = 0.002).", "user_data": {"pmid": "12401759"}}
{"text": "The number of mild hypoglycemic episodes per patient-week was 0.99 (95% CI 0.11-1.87) higher in the insulin pump group (P = 0.028).", "user_data": {"pmid": "12401759"}}
{"text": "Weight gain was similar in both groups.", "user_data": {"pmid": "12401759"}}
{"text": "Scores on the Short-Form 36-Item subscales 'general health' and 'mental health' improved in the continuous subcutaneous insulin infusion group, compared with stable values in the injection group (P = 0.048 and 0.050, respectively).", "user_data": {"pmid": "12401759"}}
{"text": "Relative risk reduction 24% (p < 0.031).", "user_data": {"pmid": "12599844"}}
{"text": "Cardiovascular mortality was reduced by 37% in favour of losartan (p < 0.028), and all cause mortality by 39% (p < 0.002).", "user_data": {"pmid": "12599844"}}
{"text": "Plasma catecholamine concentrations were lower in patients given clonidine (P<0.05) but there was no difference in cortisol concentrations.", "user_data": {"pmid": "12644413"}}
{"text": "Pioglitazone therapy was associated with significant increases in insulin sensitivity (reduced insulin resistance), whereas glimepiride had no effect.", "user_data": {"pmid": "15220012"}}
{"text": "The incidence of weight gain was not significantly different between treatment groups.", "user_data": {"pmid": "15220012"}}
{"text": "Daytime frequency, nocturia, and pain by visual analog scale decreased by 44%, 45%, and 79%, respectively (P <0.01).", "user_data": {"pmid": "15533466"}}
{"text": "The first desire to void and maximal cystometric capacity increased by 58% and 57%, respectively (P <0.01).", "user_data": {"pmid": "15533466"}}
{"text": "Patients in the vitamin E group had a higher risk of heart failure (RR, 1.13; 95% CI, 1.01-1.26; P = .03) and hospitalization for heart failure (RR, 1.21; 95% CI, 1.00-1.47; P = .045).", "user_data": {"pmid": "15769967"}}
{"text": "Similarly, among patients enrolled at the centers participating in the HOPE-TOO trial, there were no differences in cancer incidence, cancer deaths, and major cardiovascular events, but higher rates of heart failure and hospitalizations for heart failure.", "user_data": {"pmid": "15769967"}}
{"text": "In contrast, serum insulin levels, C-peptide levels, and serum glibenclamide profiles were not significantly different between enalapril and placebo.", "user_data": {"pmid": "15915547"}}
{"text": "In both groups, HV and HV standard deviation score HV-SDSCA increased during treatment and decreased during observation periods.", "user_data": {"pmid": "16772718"}}
{"text": "Interruption of treatment in the TOTO group did not result in a better gain in height standard deviation score H-SDSCA when compared with the TTOO group.", "user_data": {"pmid": "16772718"}}
{"text": "The rate of bone maturation was similar in the two groups.", "user_data": {"pmid": "16772718"}}
{"text": "Cox proportional hazards regression model in the whole study population identified female sex, chronic renal insufficiency, diabetes, advanced age, lower sternal thickness, osteoporosis, corticosteroid therapy, and prolonged CPB or ventilation times as predisposing factors to any of the two studied sternal complications.", "user_data": {"pmid": "17073957"}}
{"text": "56 patients were randomly assigned to each group, median follow-up was 26.5 months (interquartile range, 40), and patients in the diet group spent a median of 10.7 months (interquartile range, 11) following an sVLPD.", "user_data": {"pmid": "17472838"}}
{"text": "The hazard ratio for hospitalization was 1.50 for the dialysis group (95% CI, 1.11 to 2.01; P < 0.01).", "user_data": {"pmid": "17472838"}}
{"text": "On the primary efficacy endpoint, sildenafil-treated subjects had significantly better scores on the International Index of Erectile Function (IIEF) questions 3 and 4 than placebo (p < 0.001, both questions).", "user_data": {"pmid": "17624203"}}
{"text": "When accumulated into IIEF domains, all five domains were significant in favor of sildenafil.", "user_data": {"pmid": "17624203"}}
{"text": "In addition, sildenafil-treated subjects were more satisfied with treatment and had a higher intercourse success rate.", "user_data": {"pmid": "17624203"}}
{"text": "The walnut-enriched diet increased fasting serum glucose and lowered serum total cholesterol and LDL cholesterol from baseline (10.0 +/- 20.5 mg/dl, P = 0.04; -9.7 +/- 14.5 mg/dl, P < 0.01; and -7.7 +/- 10 mg/dl, P < 0.01, respectively), although these changes were not significant compared with those for an ad libitum diet without walnuts.", "user_data": {"pmid": "19880586"}}
{"text": "There were no significant changes in anthropometric measures, plasma A1C, and insulin sensitivity.", "user_data": {"pmid": "19880586"}}
{"text": "This result did not alter in post hoc analyses, when patients not achieving target breathing frequency (<10 breaths/min) or non-compliant patients were excluded.", "user_data": {"pmid": "19919399"}}
{"text": "QoL did not change over time.", "user_data": {"pmid": "19919399"}}
{"text": "Both groups were similar regarding age (p = 0.06, Mann-Whitney test).", "user_data": {"pmid": "19958108"}}
{"text": "There was no statistic difference between both groups (p = 0.44).", "user_data": {"pmid": "19958108"}}
{"text": "Pupil diameter was greater than 7 mm in all patients (100%).", "user_data": {"pmid": "19958108"}}
{"text": "Results were not statistically significant different [group I: mean decrease log MAR 95% CI (0.06; 0.32), group II: (-0.02; 0.11)].", "user_data": {"pmid": "21243370"}}
